![Medical News Asia | Powered by ['mediPr]](https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png)
Vaccination Strategies and Management Against Omicron Outbreak
There is no excerpt because this is a protected post.
Entries by Connie TANG
Dosing issues with DOACs in Asian real world setting
There is no excerpt because this is a protected post.
Anti-TNF Therapy Correlated with Better Outcomes in IBD Patients with COVID-19
The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Crohn’s disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) that have an increasing incidence and prevalence in different regions around the world.
The use of COVID-19 vaccines in children and adolescents
There is no excerpt because this is a protected post.
HPV immunisation in UK lowers the incidence of cervical cancer and CIN3
Human papillomavirus (HPV) can cause cervical cancer, anogenital cancers and head and neck cancers if long-lasting infections are triggered by high-risk HPV strains, accounting for the great burden of HPV-related cancers worldwide with an estimated incidence in 570,000 women and 600,000 men each year.
Sotorasib approved as the first targeted therapy for KRAS-Mutant Lung Cancer
Lung cancer is one of the leading cancers in Hong Kong, accounting for 26.4% of cancer mortality in 2018. Approximately 80% of the lung cancers are non-small cell lung cancer (NSCLC).
Amivantamab in combination with Lazertinib showed efficacy in NSCLC
Non-small cell lung cancer (NSCLC) accounts for 80-85% of all lung cancer. The most frequent genetic mutation harboured in lung adenocarcinomas occurs in the epidermal growth factor receptor (EGFR), accounting for 40-55% in Asian patients.
Gender-related differences in safety after switching to BIC/TAF/FTC
Human immunodeficiency virus (HIV), one of most serious public health challenges in the world, has already affected approximately 37.6 million people across the globe in 2020 and new infections in 2020 are estimated to be 1.5 million. Bictegravir/ Emtricitabine/ tenofovir (BIC/TAF/FTC) is a fixed-dose combination tablet consisting of an integrase inhibitor and two nucleoside reverse transcriptase inhibitors for the treatment of HIV infection. This HIV medication was approved by the United States Food and Drug Administration (USFDA) in 2018 due to the excellent efficacy outcomes in clinical trials. Real-world safety data of BIC/TAF/FTC was presented at the 18th European AIDS Conference in 2021 and summarised below.